Neoadjuvant chemotherapy in locally advanced breast cancer

✍ Scribed by Singh, Gurpreet; Singh, Deepinder P.; Gupta, Devender; Muralikrishna, Bhavaraju V.

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 403 KB
• Volume: 61
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199601)61:1<38::aid-jso9>3.0.co;2-t

✦ Synopsis

Thirty-eight patients with locally advanced breast cancer (Stage HI) were treated over a 3-year period. All patients initially received two cycles of CMF (cyclophosphamide, 100 mg/m2 p.0. dl-14; methotrexate 40mg/m2 intravenously (iv), d l and d8., 5 Fluorouracil 500 mg/m2 iv d l and d8). They were then subjected to surgery and external beam irradiation to the chest field and drainage areas. Four more cycles of chemotherapy completed the treatment protocol. A response to initial chemotherapy was seen in 75.7% patients, with two patients achieving a complete response. No patient had disease progression while on chemotherapy. Tumor reduction of a degree to allow breast conservation procedures was seen in eight patients. The chemotherapy was well tolerated. Twelve patients failed to complete the treatment protocol. Follow-up for the remaining 26 ranges from 9 4 0 months (mean 18 months). Ten patients developed a recurrence. Of those, only one had isolated local recurrence, two had local and systemic recurrence, and seven had systemic disease alone. Patients with recurrence were salvaged with further chemotherapy (Adriamycin and cyclophosphamide).